Close

Chardan Capital Markets Positive on Alnylam (ALNY) as ASH Data Reinforces Potential for RNAi Across Hemophilia and AIP

December 5, 2016 8:30 AM EST Send to a Friend
Chardan Capital Markets analyst Madhu Kumar reiterated a Buy rating and $89 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login